Lyterian Therapeutics

Lyterian Therapeutics derives its name from the Greek word or luterios, that defines the termination, healing, or end of disease. Disease resolution is coordinated by endogenous and exogenous agents that recruit cells and other effectors to the site of injury. We are inspired to learn from the logic that orchestrates homeostatic equilibria and fosters healing in response to disease. At Lyterian Therapeutics, we are committed to developing medicines for patients in need by co-opting physiologically relevant protein homeostatic mechanisms to regulate genetically validated targets

Biotechnology and pharmaceuticals

Lyterian therapeutics operates in the Biotechnology research industry.

Lyterian therapeutics's revenue is 11m - 100m

Lyterian therapeutics has 11 - 50 employees.